MX2022000209A - Uso de ibrutinib en el tratamiento del sindrome de bronquiolitis obliterante. - Google Patents

Uso de ibrutinib en el tratamiento del sindrome de bronquiolitis obliterante.

Info

Publication number
MX2022000209A
MX2022000209A MX2022000209A MX2022000209A MX2022000209A MX 2022000209 A MX2022000209 A MX 2022000209A MX 2022000209 A MX2022000209 A MX 2022000209A MX 2022000209 A MX2022000209 A MX 2022000209A MX 2022000209 A MX2022000209 A MX 2022000209A
Authority
MX
Mexico
Prior art keywords
treating
host disease
methods
versus host
graft versus
Prior art date
Application number
MX2022000209A
Other languages
English (en)
Inventor
Ryan Flynn
Bruce R Blazar
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2022000209A publication Critical patent/MX2022000209A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describen aquí métodos para tratar y evitar enfermedad crónica de injerto versus anfitrión impulsada por aloanticuerpo (cGVHD). Los métodos incluyen administrar a un individuo en necesidad de los mismos ibrutinib para tratar y evitar enfermedad de injerto versus anfitrión impulsada por aloanticuerpo.
MX2022000209A 2013-12-02 2016-05-27 Uso de ibrutinib en el tratamiento del sindrome de bronquiolitis obliterante. MX2022000209A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361910944P 2013-12-02 2013-12-02
US201461973178P 2014-03-31 2014-03-31

Publications (1)

Publication Number Publication Date
MX2022000209A true MX2022000209A (es) 2022-02-03

Family

ID=53270044

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006955A MX2016006955A (es) 2013-12-02 2014-12-02 Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo.
MX2022000209A MX2022000209A (es) 2013-12-02 2016-05-27 Uso de ibrutinib en el tratamiento del sindrome de bronquiolitis obliterante.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016006955A MX2016006955A (es) 2013-12-02 2014-12-02 Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo.

Country Status (14)

Country Link
US (4) US20150157634A1 (es)
EP (1) EP3076975A4 (es)
JP (4) JP2017501140A (es)
KR (2) KR20160085817A (es)
CN (2) CN105939717B (es)
AU (3) AU2014360758B2 (es)
BR (1) BR112016012158A2 (es)
CA (2) CA2932255C (es)
EA (1) EA201691020A1 (es)
IL (3) IL292522A (es)
MX (2) MX2016006955A (es)
PH (1) PH12016501051A1 (es)
TW (3) TW202402295A (es)
WO (1) WO2015084857A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3218491A1 (en) 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
EP3060218A4 (en) * 2013-10-25 2017-07-19 Pharmacyclics LLC Methods of treating and preventing graft versus host disease
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
ES2863700T3 (es) * 2016-03-22 2021-10-11 Mayo Found Medical Education & Res Uso de inhibidores de ácido graso sintasa para tratar la fibrosis
WO2018002958A1 (en) * 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
WO2018075888A1 (en) * 2016-10-21 2018-04-26 Regents Of The University Of Minnesota Materials and methods for treating or preventing graft-versus-host-disease
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
US20240025990A1 (en) * 2020-12-01 2024-01-25 City Of Hope Prevention and treatment of graft-versus-host disease (gvhd)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060182723A1 (en) * 2005-01-25 2006-08-17 Spellberg Brad J Methods for treating refractory infections in neutropenic individuals
CA2636696A1 (en) * 2006-01-13 2007-08-02 Pharmacyclics, Inc. Inhibitors of tyrosine kinases and uses thereof
DK2081435T3 (en) * 2006-09-22 2016-08-15 Pharmacyclics Llc INHIBITORS OF BRUTON'S TYROSINKINASE
ES2660418T3 (es) * 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
WO2010126960A1 (en) * 2009-04-29 2010-11-04 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
AU2010286361A1 (en) * 2009-08-31 2012-03-15 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
KR101580714B1 (ko) * 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
EP2729466B1 (en) * 2011-07-08 2015-08-19 Novartis AG Novel pyrrolo pyrimidine derivatives
WO2013155347A1 (en) * 2012-04-11 2013-10-17 Izumi Raquel Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
CA3172599A1 (en) * 2012-05-25 2013-11-28 Sloan Kettering Institute For Cancer Research Anti-ceramide antibody and antigen binding fragment thereof
CN104994875B (zh) * 2013-02-15 2018-10-09 免疫医疗公司 嵌合和人源化抗组蛋白抗体
EP3060218A4 (en) * 2013-10-25 2017-07-19 Pharmacyclics LLC Methods of treating and preventing graft versus host disease
BR122023020985A2 (pt) * 2015-03-03 2023-12-26 Pharmacyclics Llc Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton

Also Published As

Publication number Publication date
IL292522A (en) 2022-06-01
PH12016501051A1 (en) 2016-08-15
CN110478353B (zh) 2022-12-30
KR20230104754A (ko) 2023-07-10
KR20160085817A (ko) 2016-07-18
AU2014360758A1 (en) 2016-06-16
CN105939717B (zh) 2019-09-13
US20230100137A1 (en) 2023-03-30
JP2024072291A (ja) 2024-05-27
US20210177854A1 (en) 2021-06-17
US20150157634A1 (en) 2015-06-11
EP3076975A1 (en) 2016-10-12
IL276683A (en) 2020-09-30
EP3076975A4 (en) 2017-05-03
US20180078558A1 (en) 2018-03-22
TW201605454A (zh) 2016-02-16
TW202228700A (zh) 2022-08-01
TW202402295A (zh) 2024-01-16
CN105939717A (zh) 2016-09-14
AU2022203810A1 (en) 2022-06-23
JP2023029899A (ja) 2023-03-07
CA2932255A1 (en) 2015-06-11
AU2014360758B2 (en) 2020-03-26
CA3210338A1 (en) 2015-06-11
AU2020204276A1 (en) 2020-07-16
IL245715A0 (en) 2016-07-31
BR112016012158A2 (pt) 2017-09-26
WO2015084857A1 (en) 2015-06-11
CN110478353A (zh) 2019-11-22
TWI743019B (zh) 2021-10-21
MX2016006955A (es) 2016-09-07
JP2020105181A (ja) 2020-07-09
JP2017501140A (ja) 2017-01-12
CA2932255C (en) 2023-10-10
EA201691020A1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
ZA202208792B (en) Methods of treating and preventing graft versus host disease
PH12016501051A1 (en) Methods of treasting and preventing alloantibody driven chronic graft versus host disease
MX2017003933A (es) Metodos de tratamiento de la enfermedad hepatica.
CL2015003731A1 (es) Inhibidores de bromodominios
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
MX2015014431A (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer.
PH12015502087A1 (en) Newcastle disease viruses and uses thereof
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
PH12014501844B1 (en) Peptidomimetic macrocycles
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
AU2012229123A8 (en) Methods of treating breast cancer with anthracycline therapy
HK1215540A1 (zh) 用於治療或預防疾病的因子 蛋白、因子 蛋白及其抑制劑
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
IN2014DN08385A (es)
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
EA201690445A1 (ru) Лечение рака
MX369455B (es) Métodos mejorados para tratamiento de grano con ozono.
ES2586805T3 (es) Análogos de péptidos para tratar enfermedades y trastornos
BR112013032188A2 (pt) composição, produto e método para tratar pacientes com hepatite c crônica
UA86338U (ru) Способ лечения беременных с гестационным диабетом